<prompt> Tildrakizumab was approved by FDA in 2018 forCystic fibrosisMigraineHypeensionPsoriasis  <response>: Tildrakizumab was approved by FDA in 2018 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy 